San Diego, CA, United States of America

Mingkuan Chen

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Scripps Research Institute. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Mingkuan Chen in Engineered Cells

Introduction

Mingkuan Chen is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of engineered cells. His innovative work has led to the creation of a patent that showcases his expertise and creativity.

Latest Patents

Mingkuan Chen holds a patent for "Engineered cells and methods of use." This patent describes engineered cells that comprise a chemical or biological moiety covalently bound to a cell surface glycan. The moiety can be selected from a group consisting of small molecules, polynucleotides, polypeptides, and antibodies. The patent also includes compositions comprising these engineered cells and methods for making and using them.

Career Highlights

Mingkuan Chen is affiliated with the Scripps Research Institute, where he has been able to apply his knowledge and skills in a collaborative research environment. His work at this prestigious institution has allowed him to explore innovative solutions in the field of cell engineering.

Collaborations

Mingkuan Chen has worked alongside notable colleagues, including Peng Wu and Jie Li. Their collaborative efforts have contributed to advancements in their respective research areas.

Conclusion

Mingkuan Chen's contributions to the field of engineered cells exemplify the impact of innovative thinking in biotechnology. His patent and work at the Scripps Research Institute highlight his role as a leading inventor in this important area of research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…